Indaptus Therapeutics Enters Stock Purchase Agreement; Closing Extended

What Happened

• Indaptus Therapeutics (INDP) announced that it entered a Stock Purchase Agreement on September 8, 2026 to sell shares in a private placement for aggregate gross proceeds of approximately $24.0 million.
• On September 29, 2026 the company and the purchasers executed Notices and Consents that extend the outside closing date under the Purchase Agreement from September 29, 2026 to October 16, 2026 and permit the company to defer and coordinate closings until the applicable conditions to closing are satisfied (but no later than the extended date).

Key Details

• Purchase Agreement originally entered: September 8, 2026.
• Aggregate gross proceeds: approximately $24.0 million (before offering expenses).
• Original Outside Date: September 29, 2026; Extended Outside Date: October 16, 2026 (extension documented September 29, 2026).
• Except for the extensions provided by the Notices and Consents, the Purchase Agreement remains unchanged and in full force.

Why It Matters

• The extension changes the expected timing of the private placement closing and related funding, which affects when the company will receive the roughly $24.0M in proceeds.
• Investors should note the delay in funding but also that the underlying terms of the stock sale were not altered aside from the timing extension.
• The company previously filed the Purchase Agreement as Exhibit 10.1 in its prior Form 8‑K (Sept. 9, 2026); the Notice of Extension and Consent is filed as an exhibit to this current report.